O)OC1C%3dCC%3dCC%3d1)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
This boronic acid targets the BTK (Bruton's tyrosine kinase) enzyme as a key pharmacophore component in Rilzabrutinib. The fluorinated phenoxyphenyl moiety contributes to the inhibitor's binding affinity to the BTK active site through hydrophobic interactions and hydrogen bonding with the kinase hinge region. The boronic acid functionality enables the formation of biaryl linkages via Suzuki-Miyaura cross-coupling reactions.
|
|---|---|
| ln Vitro |
As a synthetic intermediate, no direct in vitro biological activity data are available for this compound. However, the final drug Rilzabrutinib has demonstrated potent BTK inhibition with IC50 values in the low nanomolar range. The compound itself would not be tested in biological assays as it is a precursor; its chemical purity and reactivity are the primary evaluation parameters in pharmaceutical development.
|
| ln Vivo |
No in vivo pharmacological data have been reported for this boronic acid intermediate. The compound is not intended for direct administration in animals. Its in vivo relevance is through its incorporation into active pharmaceutical ingredients such as Rilzabrutinib, which has shown efficacy in autoimmune disease models and clinical trials for immune thrombocytopenia.
|
| Enzyme Assay |
Not applicable as this compound is a chemical intermediate. For related boronic acid-based drugs, enzyme binding assays typically involve Surface Plasmon Resonance (SPR) or fluorescence polarization to measure binding affinity to BTK or other kinases. Assays are conducted in HEPES-buffered saline with 0.01% Tween-20 at 25°C, with compounds tested in 10-point dose-response to determine Kd values.
|
| Cell Assay |
Not applicable as this compound is a synthetic intermediate. For BTK inhibitors containing this pharmacophore, cell-based assays involve treating Ramos or other B-cell lines with test compounds in RPMI-1640 with 10% FBS for 2 hours, followed by lysis and Western blotting for phosphorylated BTK and downstream PLCγ2 to assess target engagement and pathway inhibition, with IC50 values determined from densitometric analysis.
|
| Animal Protocol |
Not applicable as this compound is a chemical intermediate. Standard in vivo protocols for BTK inhibitors containing this scaffold involve oral administration to mouse models of autoimmune disease (e.g., collagen-induced arthritis) at doses of 3-30 mg/kg daily for 2-4 weeks, with assessment of clinical scores, joint histopathology, and plasma levels of inflammatory cytokines, and terminal PK sampling.
|
| ADME/Pharmacokinetics |
Limited PK data are available for this intermediate. The compound exists as a solid at room temperature and may dissolve in DMSO, ethanol, or DMF. As a boronic acid, it may undergo oxidation and hydrolysis under physiological conditions. The fluorinated phenoxy group contributes to metabolic stability. For the final drug Rilzabrutinib, oral bioavailability is favorable with moderate clearance and half-life suitable for once- or twice-daily dosing.
|
| Toxicity/Toxicokinetics |
No direct toxicology data have been reported for this compound. Boronic acids generally require careful handling as they can be irritants. Standard safety data for similar aryl boronic acids indicate potential for skin and eye irritation. In drug development, the safety profile is established at the final drug candidate stage through GLP-compliant toxicology studies, including genotoxicity and repeat-dose toxicity assessments.
|
| Additional Infomation |
This compound is a research chemical used as a key intermediate in the synthesis of BTK inhibitors including Rilzabrutinib. It is not an approved drug itself. Its primary application is in pharmaceutical R&D for Suzuki-Miyaura cross-coupling to construct biaryl structures. Purity is typically ≥98% as determined by HPLC. Storage at -20°C under inert atmosphere is recommended to prevent boronic acid oxidation.
|
| Molecular Formula |
C12H10BFO3
|
|---|---|
| Molecular Weight |
232.015407085419
|
| Exact Mass |
232.071
|
| CAS # |
1414356-30-1
|
| PubChem CID |
71014093
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C=C(C=CC=1B(O)O)OC1C=CC=CC=1
|
| InChi Key |
PSLVPUAZLINPDI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10BFO3/c14-12-8-10(6-7-11(12)13(15)16)17-9-4-2-1-3-5-9/h1-8,15-16H
|
| Chemical Name |
(2-fluoro-4-phenoxyphenyl)boronic acid
|
| HS Tariff Code |
2934.99.9027
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3100 mL | 21.5499 mL | 43.0997 mL | |
| 5 mM | 0.8620 mL | 4.3100 mL | 8.6199 mL | |
| 10 mM | 0.4310 mL | 2.1550 mL | 4.3100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
